Skip to main content
. 2013 Dec 10;19(17):2024–2039. doi: 10.1089/ars.2012.5158

FIG. 2.

FIG. 2.

Effects of Trien treatment on copper transport protein, ceruloplasmin (Cp), superoxide dismutase 1 (SOD1) activity, and MDA production. (A) Western blotting showed the protein expression levels of copper transporter 1 (CTR1), ATP7A, and ATP7B in the vehicle- and Trien-treated APP/PS1 mouse brain. GAPDH was used as an internal control. (B) Trien treatment did not significantly alter the protein levels of CTR1, ATP7A, and ATP7B in the APP/PS1 mice brain. (C) Trien administration did not affect Cp activity. (D) Trien treatment dose-dependently enhanced SOD1 activity in the cortex of APP/PS1 mice brain compared with control group. (E) Trien markedly reduced the production of MDA in the APP/PS1 mouse brain. All values are mean±SEM (n=6). *p<0.05, **p<0.01 versus the control group (one-way ANOVA post hoc Fisher's PLSD).